Analyst Expectations for Editas Medicine's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. The average price target is $15.4, representing a 30.0% decrease from the previous average price target of $22.00. The ratings are mostly bullish.
August 29, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have a mostly bullish outlook on Editas Medicine, but the average price target has decreased by 30.0%.
The decrease in the average price target suggests that analysts are less optimistic about the stock's future performance, which could potentially impact the stock price. However, the overall bullish sentiment could provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100